These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 18662191)

  • 1. Ranolazine shortens repolarization in patients with sustained inward sodium current due to type-3 long-QT syndrome.
    Moss AJ; Zareba W; Schwarz KQ; Rosero S; McNitt S; Robinson JL
    J Cardiovasc Electrophysiol; 2008 Dec; 19(12):1289-93. PubMed ID: 18662191
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of ranolazine in long-QT syndrome type 3.
    Kaufman ES
    J Cardiovasc Electrophysiol; 2008 Dec; 19(12):1294-5. PubMed ID: 18662183
    [No Abstract]   [Full Text] [Related]  

  • 3. Normalization of ventricular repolarization with flecainide in long QT syndrome patients with SCN5A:DeltaKPQ mutation.
    Windle JR; Geletka RC; Moss AJ; Zareba W; Atkins DL
    Ann Noninvasive Electrocardiol; 2001 Apr; 6(2):153-8. PubMed ID: 11333173
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ranolazine for Congenital Long-QT Syndrome Type III: Experimental and Long-Term Clinical Data.
    Chorin E; Hu D; Antzelevitch C; Hochstadt A; Belardinelli L; Zeltser D; Barajas-Martinez H; Rozovski U; Rosso R; Adler A; Benhorin J; Viskin S
    Circ Arrhythm Electrophysiol; 2016 Oct; 9(10):. PubMed ID: 27733495
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Y1767C, a novel SCN5A mutation, induces a persistent Na+ current and potentiates ranolazine inhibition of Nav1.5 channels.
    Huang H; Priori SG; Napolitano C; O'Leary ME; Chahine M
    Am J Physiol Heart Circ Physiol; 2011 Jan; 300(1):H288-99. PubMed ID: 21076026
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular basis of ranolazine block of LQT-3 mutant sodium channels: evidence for site of action.
    Fredj S; Sampson KJ; Liu H; Kass RS
    Br J Pharmacol; 2006 May; 148(1):16-24. PubMed ID: 16520744
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lidocaine attenuation testing: An in vivo investigation of putative LQT3-associated variants in the SCN5A-encoded sodium channel.
    Anderson HN; Bos JM; Kapplinger JD; Meskill JM; Ye D; Ackerman MJ
    Heart Rhythm; 2017 Aug; 14(8):1173-1179. PubMed ID: 28412158
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Atrial arrhythmogenicity in aged Scn5a+/DeltaKPQ mice modeling long QT type 3 syndrome and its relationship to Na+ channel expression and cardiac conduction.
    Guzadhur L; Pearcey SM; Duehmke RM; Jeevaratnam K; Hohmann AF; Zhang Y; Grace AA; Lei M; Huang CL
    Pflugers Arch; 2010 Aug; 460(3):593-601. PubMed ID: 20552221
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Successful treatment of a patient with symptomatic long QT syndrome type 3 using ranolazine combined with a beta-blocker.
    van den Berg MP; van den Heuvel F; van Tintelen JP; Volders PG; van Gelder IC
    Int J Cardiol; 2014 Jan; 171(1):90-2. PubMed ID: 24342415
    [No Abstract]   [Full Text] [Related]  

  • 10. Mexiletine Shortens the QT Interval in Patients With Potassium Channel-Mediated Type 2 Long QT Syndrome.
    Bos JM; Crotti L; Rohatgi RK; Castelletti S; Dagradi F; Schwartz PJ; Ackerman MJ
    Circ Arrhythm Electrophysiol; 2019 May; 12(5):e007280. PubMed ID: 31006312
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular biology of the long QT syndrome: impact on management.
    Priori SG; Napolitano C; Paganini V; Cantù F; Schwartz PJ
    Pacing Clin Electrophysiol; 1997 Aug; 20(8 Pt 2):2052-7. PubMed ID: 9272507
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ranolazine and late cardiac sodium current--a therapeutic target for angina, arrhythmia and more?
    Makielski JC; Valdivia CR
    Br J Pharmacol; 2006 May; 148(1):4-6. PubMed ID: 16520741
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ranolazine improves abnormal repolarization and contraction in left ventricular myocytes of dogs with heart failure by inhibiting late sodium current.
    Undrovinas AI; Belardinelli L; Undrovinas NA; Sabbah HN
    J Cardiovasc Electrophysiol; 2006 May; 17 Suppl 1(Suppl 1):S169-S177. PubMed ID: 16686675
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cellular basis for the electrocardiographic and arrhythmic manifestations of Timothy syndrome: effects of ranolazine.
    Sicouri S; Timothy KW; Zygmunt AC; Glass A; Goodrow RJ; Belardinelli L; Antzelevitch C
    Heart Rhythm; 2007 May; 4(5):638-47. PubMed ID: 17467634
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diastolic transient inward current in long QT syndrome type 3 is caused by Ca2+ overload and inhibited by ranolazine.
    Lindegger N; Hagen BM; Marks AR; Lederer WJ; Kass RS
    J Mol Cell Cardiol; 2009 Aug; 47(2):326-34. PubMed ID: 19371746
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Autonomic modulation and antiarrhythmic therapy in a model of long QT syndrome type 3.
    Fabritz L; Damke D; Emmerich M; Kaufmann SG; Theis K; Blana A; Fortmüller L; Laakmann S; Hermann S; Aleynichenko E; Steinfurt J; Volkery D; Riemann B; Kirchhefer U; Franz MR; Breithardt G; Carmeliet E; Schäfers M; Maier SK; Carmeliet P; Kirchhof P
    Cardiovasc Res; 2010 Jul; 87(1):60-72. PubMed ID: 20110334
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Atrial arrhythmogenesis in wild-type and Scn5a+/delta murine hearts modelling LQT3 syndrome.
    Dautova Y; Zhang Y; Sabir I; Grace AA; Huang CL
    Pflugers Arch; 2009 Jul; 458(3):443-57. PubMed ID: 19184093
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ranolazine for congenital and acquired late INa-linked arrhythmias: in silico pharmacological screening.
    Moreno JD; Yang PC; Bankston JR; Grandi E; Bers DM; Kass RS; Clancy CE
    Circ Res; 2013 Sep; 113(7):e50-e61. PubMed ID: 23897695
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term flecainide therapy in type 3 long QT syndrome.
    Chorin E; Taub R; Medina A; Flint N; Viskin S; Benhorin J
    Europace; 2018 Feb; 20(2):370-376. PubMed ID: 28339995
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Altered atrial, atrioventricular, and ventricular conduction in patients with the long QT syndrome caused by the DeltaKPQ SCN5A sodium channel gene mutation.
    Zareba W; Sattari MN; Rosero S; Couderc JP; Moss AJ
    Am J Cardiol; 2001 Dec; 88(11):1311-4. PubMed ID: 11728364
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.